Abstract PTU-134 Figure 1

coordinated, and quality of life of patient and carer was poor. All post-pilot metrics reported significant improvements. Improved efficiency evidenced by reduction in unplanned hospital admissions, increase use of alternative community services, with use of shared care plans. 83% of these achieved their preferred place of care and death in contrast to nil pre pilot.

Conclusion This pathway worked for ASLD and needs wider evaluation and consideration of similar approaches to other groups.

Disclosure of Interest None Declared.

PTU-135 ELAAR (THE ENHANCED LIVERPOOL ABDOMINAL AREA RATIO): HOW TO USE CROSS-SECTIONAL IMAGING TO ASSESS PROGNOSIS IN END-STAGE CIRRHOSIS

¹SM Alam*, ²C Farrell, ³I Patanwala, ³P Richardson, ³T Cross. ¹Gastroenterology, Royal Liverpool and Broadgreen University Hospital Liverpool UK; ²Radiology, Royal Liverpool University Hospital, Liverpool, UK; ³Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK

10.1136/qutjnl-2014-307263.209

Introduction Liver size may be important in prognostication in cirrhosis. The LAAR score has previously shown a relationship between liver size and survival but is hampered by subjectivity. The current study aimed to improve the existing score.

Methods A retrospective-prospective cohort study was performed on patients with cirrhosis. The censor point used was date of patient death or liver transplant (LT) from CT date. Time points were measured from the date of the CT scan to censor point or last clinic appointment. The enhanced Liver^{pool} to Abdomen Area Ratio (eLAAR) was derived using a software package (Carestream). eLAAR was calculated using the formula (Liver area (cm²)/Abdominal area (cm²) x 100.

Results 101 patients were identified, 66% male, median age 52 (44–60 years). The LAAR score detected progression to death/LT in our cohort at 1 year ($p = 0.02$) and at 5 years ($p = 0.03$). The intra-class correlation coefficient between 2 operators was 0.94 (95% CI 0.89–0.97). Using an optimal eLAAR cut-off of 32 eLAAR could predict death at 1 and 5 years from diagnosis, $p = 0.03$ (OR 2.51(1.08–2.51) and $p = 0.002$ (OR 3.98 95% CI 1.5–10.4). Survival curves were constructed and the log rank test showed that eLAAR was able to predict death at 1 year (Log rank 5.3, $p = 0.02$) and 5 years (log-rank, $p = 9.7$, $p = 0.002$).

Conclusion The eLAAR score offers a new paradigm to identify patients with poor prognostic criteria on cross-sectional imaging who may benefit from liver transplantation.

Disclosure of Interest None Declared.

PTU-136 DOES A NORMAL IGG INDICATE HISTOLOGICAL REMISSION IN AUTOIMMUNE HEPATITIS (AIH)?

¹VM Gordon*, ¹E McFarlane, ²A Dube, ¹D Gleeson. ¹Hepatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK; ²Histopathology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

10.1136/gutjnl-2014-307263.210

Introduction Response to immunosuppressive treatment in AIH is often monitored by measurement of serum immunoglobulin G (IgG) as well as ALT. It is commonly assumed that serum IgG level correlates with histological activity (or Ishak necroinflammatory score: NIS) on liver biopsy, the historical “gold standard”. However, only one group (Luth *et al* 2008; J of Clin 42 (8):926–930.) have examined this relationship, finding that normalisation of both serum ALT and IgG reliably predicted a NIS of <6 but not a NIS of <4 (corresponding to minimal hepatitis, seen in less than half of the patients presumed to be in remission). Here, we aimed to reassess how well serum IgG correlated with NIS in treated patients with AIH undergoing follow-up biopsy for confirmation of disease remission.

Methods We assessed 31 follow-up biopsies, performed to confirm histological remission in 28 patients with AIH (International Group criteria; Alvarez J Hepatol 1999; 31:929) on immunosuppressive treatment and an accompanying serum IgG (measured within 6 weeks of biopsy).

Results For 29 of the 31 follow-up biopsies, accompanying serum IgG was in the normal range (≤ 16 gm/L). However, only 13 of these 31 biopsies showed NIS < 4 (minimal hepatitis). On ROC analysis, area under the curve (AUC) for IgG in predicting a NIS of ≥ 4 ($n = 31$) was 0.596 ($p = 0.368$). Sensitivity and specificity of IgG (cut off > 16 grm/L) in predicting a NIS of ≥ 4 was 5.5% and 57% respectively. Corresponding positive (PPV) and negative (NPV) predictive values were only 50% and 59% respectively. AUC for change in IgG (Δ IgG: baseline values minus values accompanying follow up biopsy; $n = 29$) in predicting NIS > 4 was 0.551 ($p = 0.642$).

Defining histological remission instead as minimal or mild hepatitis- NIS ≤ 6 (as Luth's group did because they found that such patients did not develop fibrosis progression), there were still 4/29 (14%) patients with normal serum IgG who were not in histological remission. On ROC analysis, AUC for IgG in prediction of NIS ≥ 6 on follow-up biopsy ($n = 31$) was 0.62 ($p = 0.39$). PPV and NPV for serum IgG (cut off >16 gm/L) in predicting of NIS ≥ 6 was 50% and 86% respectively. AUC for Δ IgG in prediction of NIS ≥ 6 was 0.608 ($p = 0.453$).

Conclusion Normalisation of serum IgG values in patients with AIH following treatment is not predicative of histological remission. At present, this requires a liver biopsy.

Disclosure of Interest None Declared.

PTU-137 PNEUMOCOCCAL VACCINATION IN PATIENTS WITH LIVER CIRRHOSIS – IS THE MESSAGE BEING HEARD?

V Sehgal*, H Alexander, K Besherdas. *Gastroenterology, Chase Farm Hospital, London, UK*

10.1136/gutjnl-2014-307263.211